In our study, EGFR-TKIs sensitivity assessment illustrated that the lung cancer organoids respond to osimertinib and gefitinib notably, while icotinib and erlotinib have partial or little effect on the cancer organoids harboring the uncommon EGFR double mutation. The gene discussed is EGFR; the disease is cancer.